Redeye lowers its expectations and valuation on Remedy. However, we expect a steady build-up period will be initiated at the beginning of 2023 when game projects move into the next phase of development. The Remedy stock is traded at half its value since our research update in April where we lowered our estimates and valuation. As in our initial coverage report in late 2018, we yet again state that Remedy offers investors “Premium at a discount”.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/